Apigenin

芹菜素

Report date: 2023/06/27 10:17:23

Base Information

Drug NameApigenin
Drug Alias NameNSC-83244
ClassificationNatural product/Extract > Plants extract
Mechanisms of ActionMitogen-activated protein kinase inhibitorsAryl hydrocarbon receptor antagonistsNuclear factor erythroid 2-related factor 2 stimulants +[6] 
TargetsMitogen-activated protein kinaseAryl hydrocarbon receptorNuclear factor erythroid 2-related factor 2 +[6] 
Therapy Area/IndicationsAtherosclerosisUveitisHyperalgesia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth KoreaMainland ChinaJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesHenan Provincial People'S HospitalAjou UniversityQuanzhou First Hospital +[5] 
Inactive CompaniesN/A
Active IndicationsAtherosclerosisUveitisHyperalgesia +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A